Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL) »
04/12/14

BET Bromodomain Inhibition Reduces Leukemic Burden and Prolongs Survival In The EI 1/4 -TCL1 Transgenic Mouse Model Of Chronic Lymphocytic Leukemia (CLL) Independent Of TP53 Mutation Status »
04/12/14

Systematic Mapping Of Drug and Pathway Sensitivity In Chronic Lymphocytic Leukemia Identifies Synthetic Lethal Interactions Of Mutant p53 »
04/12/14

Prognostic Assessment In Patients With Chronic Lymphocytic Leukemia »
04/12/14

Updated Follow-Up In The CLL2007FMP Trial Supports The Non Superiority Of The Association Fludarabine-Cyclophosphamide (FC) Plus Campath Compared To FC Plus Rituximab and Points Out The Importance Of Minimal Residual Disease, By 6-Color Flow Cytometry Technique, On Progression Free Survival »
04/12/14

Overall Survival In Early Stage Chronic Lymphocytic Leukemia »
04/12/14

Combination Of Kinase Inhibitors »
04/12/14

Ofatumumab + Chlorambucil Versus Chlorambucil Alone »
04/12/14

Cytokine and T-Cell Phenotypic Changes Upon In Vivo Ibrutinib Therapy For CLL a€“ Targeting Both CLL Cells and The Tumor-Microenvironment »
04/12/14

Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis. »
04/12/14